Merck Sharp + Dohme Corp.

Lexicon Pharmaceuticals, Inc.

Elexopharm Gmbh

Jerry Andrew Taylor

Yusheng Xiong

Scott B Hoyt

Clare London

Andrew John Cooke

Bheemashankar A Kulkarni

Brent Whitehead

Emma Louise Carswell

Paul David Ratcliffe

Swapan Kumar Samanta

D Jonathan Bennett

Jaiqiang Cai

Brian Alexander McKittrick

Amjad Ali

Sung-Sau So

David John Augeri

Kenneth Gordon Carson

Zhicai Wu

Peter Orth

Jacqueline D Hicks

John K MacLean

Marianne Carlsen

Alexander Heim-Riether

Qinghong Fu

Theodore C Jessop

Hong Dong Chu

Matthew Lombardo

James E Tarver

Whitney Lane Petrilli

Michael Man-Chu Lo

Zhijian Lu

Rui Liang

John S Debenham

Timothy J Henderson

Ashwin Umesh Rao

Wonsuk Chang

Rolf Wolfgang Hartmann

Min K Park

Ping Lan

Sathesh P Bhat

Hyewon Youm

Markus Kristofer Dahlgren

Jason Eugene Imbriglio

Zhongxiang Sun

Ralf Heim

Revathi Reddy Katipally

Lina Yin

Qingzhong Hu

Jason Patrick Healy

Xiaoqing Han

Rohit Saxena

John MacLean

Emmanuel Bey

Xiaolian Xu

Zhe Feng

Amy Bittner McCracken

Michael Lo

Jonathan E Gable

Philip E Keyes

Min Shen

Amy Bittner Mccracken

Brent R Whitehead

John Maclean

Emma Carswell

Andrew Cooke

Jaiqiqang Cai

D Jonathan Bennet

Brent White-Head

Bey; Emmanuel

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, X, Y, R, R, R, Rand n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples. 

Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Triazolopyridyl compounds as aldosterone synthase inhibitors

This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase. 

Indazole compounds as aldosterone synthase inhibitors

This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Imidazopyridyl compounds as aldosterone synthase inhibitors

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

Aldosterone synthase inhibitors

4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed. Particular compounds are of formula I: 

4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use

O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described. Particular compounds of the invention are of formula I: 

O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer

Growing community of inventors

Trenton, NJ, United States of America

Jerry Andrew Taylor